Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study

• Sebastian Botzenhardt,
• Mariagrazia Felisi,
• Donato Bonifazi,
• Giovanni C. Del Vecchio,
• Maria C. Putti,
• Antonis Kattamis,
• Adriana Ceci,
• Ian C.K. Wong,
• Antje Neubert

Affiliations

Sebastian Botzenhardt

Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Erlangen, Germany

Mariagrazia Felisi

Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy

Donato Bonifazi

Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy

Giovanni C. Del Vecchio

Azienda Ospedaliera Universitaria Consorziale, Policlinico di Bari, Italy

Maria C. Putti

Azienda Ospedaliera di Padova, Clinica di Oncoematologia Pediatrica, Italy

Antonis Kattamis

First Department of Pediatrics, National and Kapodistrian University of Athens, Greece

Adriana Ceci

Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy;Gianni Benzi Pharmacological Research Foundation, Bari, Italy

Ian C.K. Wong

Centre for Medicines Optimisation Research and Education, Research Department of Practice & Policy, University College London School of Pharmacy, UK;Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China

Antje Neubert

Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Erlangen, Germany